{"disease":{"id":"ros1-rearrangement-non-small-cell-lung-cancer","name":"ros1 rearrangement non small cell lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05055232","title":"A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Xuanzhu Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02321501","title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}